Apellis Pharmaceuticals (APLS) PT Raised to $80 at Oppenheimer Following R&D Day
Tweet Send to a Friend
Oppenheimer analyst Justin Kim raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $80.00 (from $67.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
